By Len Zehrs Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have...
By Len Zehr Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months. “Our DepoVax...
By Len Zehr Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus...
By Len Zehr Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug...